Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens
Abstract Background Viral reactivations are frequent in hematologial patients due to their cancer‐related and drug‐induced immunosuppressive status. Daratumumab, an anti‐CD38 monoclonal antibody, is used for multiple myeloma (MM) treatment, and causes immunosuppression by targeting CD38‐expressing n...
Saved in:
| Main Authors: | Danilo De Novellis, Raffaele Fontana, Bianca Serio, Emilia Vaccaro, Roberto Guariglia, Denise Morini, Michela Rizzo, Valentina Giudice, Carmine Selleri |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-07-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.7402 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Daratumumab
by: Vishnu Gopal, et al.
Published: (2020-01-01) -
Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center
by: Shuiqing Xu, et al.
Published: (2024-12-01) -
Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01) -
Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis
by: Hua Jiang, et al.
Published: (2024-12-01) -
Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti‐CD38 Monoclonal Antibodies: A Systematic Review
by: Chia Jie Tan, et al.
Published: (2025-03-01)